A trial of durvalumab for non small cell lung cancer (ATLANTIC)
Cancer type:
Status:
Phase:
This trial looked at durvalumab for people who have had treatment for non small cell lung cancer (NSCLC) but the cancer has continued to grow.
More about this trial
Doctors often treat non small cell lung cancer that has spread with radiotherapy, chemotherapy or targeted cancer drugs.
Durvalumab (MEDI4736) is a type of targeted cancer treatment called a monoclonal antibody. It seeks out cancer cells by looking for a particular protein and attaching to it.
The researchers hoped that durvalumab would help the immune system to recognise and attack cancer cells, stopping the cancer growing.
The main aim of this trial was to find out if durvalumab helps stimulate the immune system and helps stop non small cell lung cancer growing
Summary of results
- Group 1 – people who had a change in their EGFR or ALK gene, and some of their cancer cells expressed PD-L1
- Group 2 – people who didn’t have a change in their EGFR or ALK gene, and some of their cancer cells expressed PD-L1
- Group 3 – people who didn’t have a change in their EGFR or ALK gene, and more than 90% of their cancer cells expressed PD-L1
- 111 people in group 1 - EGFR or ALK change and some of their cancer cells expressed PD-L1
- 265 people in group 2 - no EGFR or ALK change and some of their cancer cells expressed PD-L1
- 68 people in group 3 - no EGFR or ALK change and a high number of their cancer cells expressed PD-L1
The research team looked at how well the treatment worked in 409 of the people who took part.
- 4% in group 1
- 8% in group 2
- 12% in group 1
- 16% in group 2
- 31% in group 3
- 16% in group 1
- 23% in groups 2 and 3
- inflammation of the lungs (pneumonitis)
- extreme tiredness (fatigue)
- a reaction to the drug which can cause symptoms such as rash or fever (infusion reaction)

Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Peter Schmid
Supported by
AstraZeneca
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040